Skip to main content
Locate a specialist
Patient and carer information
Health professional information

ASCIA News

  • New international consensus report on anaphylaxis
    A new international consensus report on anaphylaxis has been released by the Global Allergy and Asthma Excellence Network (GA2LEN) and published open access online in the Journal of Allergy and Clinical Immunology.  The report was developed by an international panel of 46...
  • FASENRA (benralizumab) approved for eosinophilic granulomatosis with polyangiitis (EGPA)
    FASENRA® (benralizumab) has recently been approved by the Therapeutic Goods Administration (TGA) for a new indication in Australian patients, with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare form of necrotising vasculitis...
  • ALBEY venom immunotherapy available from April 2025
    Stallergenes Greer will be starting to re-establish the supply of registered ALBEY® brand venom products (Honey Bee, Paper Wasp, Yellow Jacket) in Australia. These will replace the equivalent unregistered HYMENOPTERA® brand venom products (Honey Bee, Paper Wasp, Yellow...
  • ALUSTAL immunotherapy available from April 2025
    From April 2025, registered subcutaneous immunotherapy (SCIT) treatments (ALUSTAL® HDM and ALUSTAL® 5G) will be available in Australia. These treatments are approved by the Therapeutic Goods Administration (TGA) for children, adolescents and adults with respiratory...
  • ASCIA Immunodeficiency Strategy - March 2025 update
    Since 2019 the Australasian Society for Clinical Immunology and Allergy (ASCIA) has been working together with patient/carer organisations and other stakeholders to develop the ASCIA Immunodeficiency Strategy at a national level for both Australia and New Zealand (the...
  • National Allergy Council projects allocated to ASCIA - March 2025 update
    The National Allergy Council is a partnership between the Australasian Society of Clinical Immunology and Allergy (ASCIA) and Allergy & Anaphylaxis Australia (A&AA), funded by the Australian Government Department of Health and Aged Care to implement the National Allergy...
  • New ARISE allergic rhinitis (hay fever) trial
    General practices and allergy clinics across Australia are invited to take part in a new clinical trial aiming to improve the lives of young people with hay fever, our country’s most common allergic disease.  Recruitment sites in every state and territory have partnered...
  • Shingrix Vaccine to Prevent Shingles - Update
    Shingrix®  is a varicella zoster virus recombinant vaccine that can provide protection from herpes zoster (shingles) and post-herpetic neuralgia (long-term nerve pain): Advice for Health Care Professionals with regards to patient eligibility for the Shingles NIP can now be...
More ASCIA News
ASCIA Member Login
Site last updated: 2 April 2025
 

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.

Join our mailing list or see latest edition here...